< Back
References
Next >

Home‍ ‍Screening‍ ‍MRD + Monitoring‍ ‍‍ ‍Treatment Selection

Guardant delivers clinically actionable insights - revealing what's missed with genomics alone

Clinical Actionability in mCRC
(% of patients with immediate actionable findings)
Genomics Alone
Combined Genomics and Epigenomics*
Likelihood of no FDA-approved biomarkers
└──────┘
44% increase in
clinical actionability
(% of patients with immediate actionable findings)
Find more actionable insights with Guardant360 Liquid CDx